safranal has been researched along with Huntington Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abd El-Salam, DM; Hussein, RM; Rizk, SM; Shehata, NI | 1 |
| Feligioni, M; Fotoohi, A; Hassanzadeh, K; Hosseini, S; Izadpanah, E; Moloudi, MR | 1 |
2 other study(ies) available for safranal and Huntington Disease
| Article | Year |
|---|---|
Effect of safranal or candesartan on 3-nitropropionicacid-induced biochemical, behavioral and histological alterations in a rat model of Huntington's disease.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Corpus Striatum; Disease Models, Animal; Huntington Disease; Motor Activity; Neuroprotective Agents; Nitro Compounds; Propionates; Rats; Rats, Wistar | 2023 |
A Novel Pharmacological Protective Role for Safranal in an Animal Model of Huntington's Disease.
Topics: Animals; Antioxidants; Behavior, Animal; Body Weight; Catalase; Cerebral Cortex; Cyclohexenes; Glutathione; Huntington Disease; Locomotion; Male; Malondialdehyde; Mastication; Neuroprotective Agents; Nitro Compounds; Propionates; Rats, Wistar; Rotarod Performance Test; Superoxide Dismutase; Terpenes | 2021 |